Ikaria Bioscience

Ikaria was a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies and drug-device combinations for critically ill patients in the hospital and ICU settings. The company's flagship product, INOmax (nitric oxide) for inhalation, is a vasodilator indicated for the treatment of hypoxic respiratory failure in term and near-term neonates. Beyond its commercial portfolio, Ikaria maintained an R&D pipeline focused on critical care medicine before spinning off its research assets into Bellerophon Therapeutics. The company was acquired by Mallinckrodt in 2015 for approximately $2.3 billion to bolster Mallinckrodt's hospital platform.